HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jan. 28, 2020-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter and nine months ended December 31, 2019 , after the close of market on Monday, February 3, 2020 .
(NDC 51672-4131-1) Lot # 331771 (Expiration June 2021 ) Due to Cross-Contamination With Enalapril Maleate HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jan. 10, 2020-- Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling one (1) lot of Lamotrigine 100 mg Tablets, Lot # 331771
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Dec. 19, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today announced the final results of its modified “Dutch auction” tender offer to repurchase up to $225 million in value of its ordinary shares, nominal (par) value NIS
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Dec. 17, 2019-- Third paragraph, second sentence of release should read: "...announced until at least December 19, 2019 ..." (instead of announced until at least December 19, 2020 ...). The corrected release reads: TARO ANNOUNCES PRELIMINARY RESULTS OF ITS TENDER
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Dec. 6, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today that it has accepted the resignation of its Chief Financial Officer, Mariano Balaguer , effective January 3, 2020 . Mr.
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Nov. 15, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today that it has commenced a modified “Dutch auction” tender offer to repurchase up to $225 million in value of its ordinary shares at a price not greater than
Board of Directors Approves $300 Million Share Repurchase Program HAWTHORNE, N.Y. --(BUSINESS WIRE)--Nov. 4, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and six months ended September 30, 2019 .
Earnings Call to Discuss Results to be Conducted Tuesday, November 5 at 8:00 am ET HAWTHORNE, N.Y. --(BUSINESS WIRE)--Oct. 25, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for quarter and six months ended September 30, 2019 ,
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Aug. 8, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2019 . Quarter ended June 30, 2019 Highlights - compared to June 30, 2018 Net sales of $161.3
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jul. 31, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2019 , after the close of market on Thursday August 8, 2019 .
Alerts are e-mailed to you whenever certain new company information is posted to this site.
